Business Context and Reporting Period
This Form 8-K is a current report filed by Landec Corporation (not Lifecore Biomedical, Inc., as indicated in the metadata) on January 28, 2021. The filing addresses the departure of a senior officer and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the specific severance package for the departing officer:
- Salary Continuation: Aggregate amount of $350,000 payable over one year in equal monthly installments.
- Healthcare: Continuation payments for up to one year.
- Equity: Accelerated vesting of 2020 stock options for shares that would have vested over the subsequent 12-month period.
Material Changes
The primary material change reported is the retirement of Brian McLaughlin, who served as Chief Financial Officer and Secretary, effective January 18, 2021. This departure was previously announced, and this filing details the formal Separation and General Release agreement executed on January 28, 2021.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of general corporate risks. The only contingency noted is that the Separation Agreement is subject to revocation by Mr. McLaughlin until February 5, 2021. The agreement includes a customary cooperation covenant and a general release of claims against the Company.
Investor Verification Checklist
- Verify the identity of the registrant as Landec Corporation (Ticker: LNDC) rather than Lifecore Biomedical, Inc.
- Confirm the effective date of the CFO's departure (January 18, 2021) and the interim leadership structure.
- Review the attached Exhibit 10.1 (Separation and General Release) for full terms of the $350,000 severance and option vesting acceleration.
- Monitor whether the Separation Agreement is revoked by the February 5, 2021 deadline.